中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

46 records (took 0.018 seconds)

    Crystalline Solid Forms of N--N'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, Processes for Making, and Methods of Use
    5.
    发明申请
    Crystalline Solid Forms of N--N'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, Processes for Making, and Methods of Use 审中-公开
    N-N' - （4-氟苯基）环丙烷-1,1-二甲酰胺的结晶固体形式，制备方法和使用方法

    公开(公告)号：US20170044106A1

    公开(公告)日：2017-02-16

    申请号：US15118738

    申请日：2015-02-16

    Applicant: Exelixis, Inc.

    Inventor： Dana T. Aftab ,  Nathan Guz ,  Stephen Lau ,  Noel Hamill ,  Tracy Walker ,  Jana Galbraith ,  Simon Yau ,  Khalid Shah

    IPC: C07D215/233

    CPC classification number: C07D215/233 ,  C07B2200/13 ,  C07D215/22

    Abstract: The invention relates to novel crystalline solid forms of the chemical compound N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N′-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide (Compound 1), and solvates thereof, including hydrates, that are useful for the treatment of cancer. Also disclosed are pharmaceutical compositions comprising the crystalline solid forms and processes for making the crystalline solid forms, as well as methods of using them for the treatment of cancer, particularly thyroid cancer, prostate cancer, hepatocellular cancer, renal cancer, and non-small cell lung carcinoma. The crystalline solid forms can be used to make the L-malate salt of cabozantinib.

    Abstract translation: 本发明涉及化合物N- {4 - [（6,7-二甲氧基喹啉-4-基）氧基]苯基} -N' - （4-氟苯基）环丙烷-1,1-二甲酰胺（ 化合物1）及其溶剂化物，包括水合物，其可用于治疗癌症。 还公开了包含结晶固体形式和用于制备结晶固体形式的方法的药物组合物，以及其用于治疗癌症，特别是甲状腺癌，前列腺癌，肝细胞癌，肾癌和非小细胞的方法 肺癌。 结晶固体形式可用于制备卡泊沙坦的L-苹果酸盐。

    Method of Treating Lung Adenocarcinoma
    6.
    发明申请
    Method of Treating Lung Adenocarcinoma 审中-公开
    肺腺癌的治疗方法

    公开(公告)号：US20170042880A1

    公开(公告)日：2017-02-16

    申请号：US15305854

    申请日：2015-04-27

    Applicant: Exelixis, Inc.

    Inventor： Dana T. Aftab ,  Peiwen Yu

    IPC: A61K31/47 ,  C12Q1/68

    CPC classification number: A61K31/47 ,  A61K31/337 ,  A61K31/517 ,  A61K31/7068 ,  C12Q1/6886 ,  C12Q2600/158 ,  A61K2300/00

    Abstract: This invention is directed to the treatment of cancer in a patient, particularly a patient with lung adenocarcinoma, and more particularly a patient with SLC34A2-ROS1, CD74-ROS1, or FIG-ROS1 fusion-positive non-small cell lung cancer, with an inhibitor of MET, VEGFR2, and ROS1 which is a compound of Formula (I): or a pharmaceutically acceptable salt thereof.

    Abstract translation: 本发明涉及治疗患者，特别是患有肺腺癌的患者，特别是患有SLC34A2-ROS1，CD74-ROS1或FIG-ROS1融合阳性非小细胞肺癌的患者，其具有 其为式（I）化合物的MET，VEGFR2和ROS1抑制剂：或其药学上可接受的盐。

Patent Agency Ranking